RVSV-ZEBOV vaccine

From WikiMD's WELLNESSPEDIA

RVSV-ZEBOV vaccine is a vaccine used to protect against Ebola virus disease. It was developed by the Public Health Agency of Canada and is now licensed to Merck & Co. The vaccine is a recombinant, replication-competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus.

Development[edit]

The development of the RVSV-ZEBOV vaccine began in the early 2000s at the National Microbiology Laboratory of the Public Health Agency of Canada. The vaccine was then licensed to NewLink Genetics, which was subsequently acquired by Merck & Co.

Efficacy[edit]

The RVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola virus disease in clinical trials. A trial conducted in Guinea during the 2014-2016 Ebola outbreak showed that the vaccine was highly effective.

Usage[edit]

The RVSV-ZEBOV vaccine is used in a "ring vaccination" approach, where all people who have come into contact with an Ebola patient are vaccinated to prevent the spread of the disease. It is also used to vaccinate healthcare workers who are at high risk of infection.

Side Effects[edit]

Common side effects of the RVSV-ZEBOV vaccine include headache, fatigue, muscle pain, and fever. Serious side effects are rare but can include allergic reactions.

See Also[edit]


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.